Benzinga | May 25, 2021 08:07AM EDT

Corbus Pharmaceuticals To Present Two Abstracts At EULAR 2021 Virtual Congress

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021.



Details of the presentations are as follows:

Presentation Title Phase 3 Trial of Lenabasum, a CB2 Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Session: Progress in myositis and scleroderma research - I

Date: Thursday, June 3, 2021

Presentation Time: 10:25 a.m. - 10:32 a.m. CEST (4:25 a.m. -- 4:32 a.m. EDT)

Presenter Robert Spiera, M.D., Director of the Scleroderma, Vasculitis, and Myositis Program at the Hospital for Special Surgery, Weill Cornell Medical College and Co-Principal Investigator of Corbus' Phase 3 RESOLVE-1 study in systemic sclerosis

Abstract Number: OP0171

Poster Title Long-term Safety and Efficacy of Lenabasum during 3 Years in an Open-Label Extension (OLE) of a Phase 2 Study of Lenabasum in Refractory Skin Disease in Dermatomyositis (DM)

Session: Scleroderma, myositis and related syndromes

Date: Saturday, June 5, 2021

Presentation Time: 10:30 a.m. - 10:36 a.m. CEST (4:30 a.m. -- 4:36 a.m. EDT)

Presenter Victoria Werth, M.D., Professor of Dermatology and Medicine at the University of Pennsylvania Perelman School of Medicine and Co-Principal Investigator of Corbus' Phase 3 DETERMINE study in dermatomyositis

Abstract Number: POS0315

The abstracts are published in the EULAR 2021 Abstract Archive on the conference website. EULAR presentations are under embargo until 00:01 GMT+1 on June 2, 2021. Once the presentations are made public, they will be available on the Company's website in the Scientific Conferences section.